3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
4
Pain, Postoperative
2
Vesico-Ureteral Reflux
1
Uterine Neoplasms
1
Ureteral Neoplasms
1
Peritoneal Cancer
1
Pancreatic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Neuralgia
1
Nephrolithiasis
1
Neoplasms
1
Malignant Neoplasms of Female Genital Organs
1
Lung Neoplasms
1
Leiomyoma
1
Kidney Neoplasms
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Digestive System Diseases
1
Breast Cancer Female
1
Abdominal Cancer
1
Interventions
Tamoxifen
2
pegfilgrastim
1
exemestane
1
abemaciclib
1
Tretinoin
1
Tocopherols
1
Standard of Care
1
Mifepristone
1
Letrozole
1
Isotretinoin
1
Dexmedetomidine
1
Cannabidiol
1
Bupivacaine
1
Anastrozole
1
Alitretinoin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Breast Cancer Female
×
Bupivacaine
×
Clear all
NCT03063073
2026-02-12
pec's
South Egypt Cancer Institute
Phase 3
Completed
60 enrolled